The present invention provides a salt of demethyl tramadol, i.e., a compound represented by formula (I) or a solvate thereof, a pharmaceutical composition comprising the compound represented by formula (I) or the solvate thereof, and a use of the compound represented by formula (I) or the solvate thereof or the pharmaceutical composition in the treatment of moderate to severe pain. The compound or pharmaceutical composition of the present invention can stably release a drug having analgesic activity in a body for a long period of time, can be conveniently used by doctors and patients while exerting pharmacological effects, and has good medication compliance.

##STR00001##

The present invention provides a salt of demethyl tramadol, i.e., a compound represented by formula (I) or a solvate thereof, a pharmaceutical composition comprising the compound represented by formula (I) or the solvate thereof, and a use of the compound represented by formula (I) or the solvate thereof or the pharmaceutical composition in the treatment of moderate to severe pain. The compound or pharmaceutical composition of the present invention can stably release a drug having analgesic activity in a body for a long period of time, can be conveniently used by doctors and patients while exerting pharmacological effects, and has good medication compliance.

##STR00001##

The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.

The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.

Provided are pamoate salts of ketamine having a stoichiometry of 2:1 of ketamine to pamoate, including R, S-ketamine pamoate, S-ketamine pamoate, or R-ketamine pamoate, and crystalline or amorphous forms of the pamoate salts, and having excellent safety and properties for pharmaceutical applications. Also provided are pharmaceutical compositions including the pamoate salts of ketamine and their uses in treating a CNS disease or serving as an anesthetic.

The invention is directed at esylate and salicylate salts of cis-N-cyclohexyl-N-ethyl-3-(3-chloro-4-cyclohexylphenyl)prop-2-enylamine and their pharmaceutical composition. The invention is also directed at the use esylate and salicylate salts of cis-N-cyclohexyl-N-ethyl-3-(3-chloro-4-yclohexylphenyl)prop-2-enylamine and their pharmaceutical composition in treatment of myelin-related disorders.

The invention provides certain nicotine salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, certain nicotine salt-co-crystals are described, including nicotine and two different coformers. The invention further provides methods of preparation and characterization of nicotine salts, co-crystals, and salt co-crystals. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.

The invention provides certain nicotine salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, certain nicotine salt-co-crystals are described, including nicotine and two different coformers. The invention further provides methods of preparation and characterization of nicotine salts, co-crystals, and salt co-crystals. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.

The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

The present invention relates to a new preparation method for escitalopram pamoate ((S)-(+)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-cyanoisob enzofuran pamoate), wherein the method is environmentally friendly and pollution-free, and the escitalopram pamoate prepared by means of the method has a high purity and a good repeatability.